1Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana.
2Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie, Institut Hospitalo-Universitaire, Méditerranée Infection, Marseille, France.
Am J Trop Med Hyg. 2021 May 3;104(6):2091-2096. doi: 10.4269/ajtmh.19-0591.
Cutaneous leishmaniasis (CL) is firmly established in South America. We aimed to assess the detection of IgG antibodies against 14 and/or 16 kDa antigens by immunoblot (IB) for CL serological diagnosis in French Guiana, an area where many endemic pathogens could interfere with it. This study was performed retrospectively on sera from 141 patients at the Cayenne tertiary hospital: 30 were patients with confirmed CL, 71 were diagnosed with various other endemic pathogens, 11 were diagnosed with an autoimmune disease, and 29 controls had no history of CL. Antibodies bound to the 14 and/or 16 kDa antigens in 27 of the 30 CL patients' sera and in 39 of the 111 non-CL patients' sera (26 from the infectious diseases group, four from the autoimmune diseases group, and nine from the dermatology department). The method tested showed a high sensitivity (90%) and a low specificity (66%), and a diagnosis odds ratio of 17.5 (95% CI [4.6-78.0]). This IB may be helpful to exclude the diagnosis of CL, prompting physicians to look for another diagnosis in the case of a negative IB.
皮肤利什曼病(CL)在南美洲已得到充分证实。我们旨在评估免疫印迹(IB)检测 14 和/或 16 kDa 抗原的 IgG 抗体在法属圭亚那 CL 血清学诊断中的应用,该地区存在许多地方性病原体可能会对其产生干扰。这项研究是在卡宴三级医院的 141 例患者的血清中进行的回顾性研究:30 例为确诊 CL 的患者,71 例为诊断出各种其他地方性病原体的患者,11 例为诊断出自身免疫性疾病的患者,29 例为无 CL 病史的对照组。在 30 例 CL 患者的血清中和 111 例非 CL 患者的血清(26 例来自传染病组,4 例来自自身免疫性疾病组,9 例来自皮肤科)中,有 27 例和 39 例血清与 14 和/或 16 kDa 抗原结合。该方法检测到的灵敏度很高(90%),特异性较低(66%),诊断比值比为 17.5(95%CI[4.6-78.0])。这种 IB 可能有助于排除 CL 的诊断,在 IB 为阴性的情况下,促使医生寻找其他诊断。